Proceeds to Fund U.S. Clinical Trials of Trilobal Tissue Heart Valve and
IRVINE, Calif., Jan. 28 /PRNewswire/ -- Arbor Surgical Technologies, Inc., a privately held medical device company, announced today the closing of a $20 million dollar Series C financing round. Medtronic Inc. led the investment as part of a licensing agreement that was reached between the two companies. The agreement provides Medtronic with manufacturing, marketing and distribution rights to Arbor's advanced trilobal pericardial valve technologies. Financial terms of the license agreement have not been disclosed. Arbor retains exclusive rights to the modular Trilogy(TM) Aortic Valve System and sutureless TRE(TM) implantation technologies. "I am truly excited about this opportunity." said Dr. John Liddicoat, Vice President and General Manager of Medtronic Structural Heart Disease. "No other comparable technology is on the horizon." Existing Arbor investors also participated in this new round of financing. With the closing of this event, Arbor has raised approximately $54 million dollars to date.
"We are excited to complete this milestone round of financing. Recognition from such a major player in the industry confirms the value of our technology," said Steve Bacich, President and Chief Executive Officer of Arbor. "This financing event will allow us to expand clinical trials of our core technologies, the Trilogy(TM) Aortic Valve System and the sutureless TRE(TM) implantation tool. These devices are designed to enable more surgeons to perform minimally invasive heart valve procedures. We believe that the adoption of Arbor's products will improve the lives of heart valve patients worldwide."
About Arbor Surgical Technologies, Inc.
Arbor Surgical Technologies, Inc., (http://www.arborsurgical.com) with
facilities in Irvine and Portola Valley, CA (USA), is a privately held
cardiovascular device company focused on the minimally invasive heart valve
replacement market. Founded in 2002 by Dr. Thomas J. Fogarty and noted
valve designer, Ernie Lane, Arbor is developing technologies intended to
deliver significant clinical benefits to patients worldwide. The
Trilogy(TM) Aortic Valve System and TRE(TM) attachment technologies are
designed to expand the use of minimally invasive heart valve procedures.
President and CEO of Arbor Surgical Technologies, Inc.
|SOURCE Arbor Surgical Technologies, Inc.|
Copyright©2008 PR Newswire.
All rights reserved